Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis

NCT00303381 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Interferon-beta-1a, 44 microgram
DRUG: Placebo
DRUG: Interferon-beta-1a, 66 microgram

Sponsor

EMD Serono

Collaborators

[object Object]